---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-034777"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2022-10-20T23:59:59+00:00"
generated_at: "2026-06-23T02:11:17.738476+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS CEO to retire Dec 31; appoints new CEO David Angulo and CFO Ivor Macleod

## Summary
- CEO Marco Taglietti to retire Dec 31, 2022; separation extends stock option exercise period to 4 years.
- David Angulo (CMO) becomes President & CEO Jan 1, 2023; salary $565K, bonus 55%, option 165K shares, RSU 110K shares.
- Ivor Macleod joins as CFO Oct 24, 2022; salary $435K, bonus 40%, option 170K shares, RSU 15K shares.
- Interim CFO Larry Hoffman to step down; Chief Commercial Officer Christine Coyne to depart Nov 30, 2022.
- Company to out-license BREXAFEMME, wind down promotion, focus ibrexafungerp on hospital indications.

## SEC filing metadata
- accession: 0001564590-22-034777
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2022-10-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000156459022034777/0001564590-22-034777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000156459022034777/scyx-8k_20221014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-034777
- JSON: https://secwatch.observer/filing/0001564590-22-034777.json
- Plain text: https://secwatch.observer/filing/0001564590-22-034777.txt

## Key facts
- Executive change
  David Angulo changed role as President and Chief Executive Officer at SCYNEXIS INC.
  - Action: become
  - Role: President and Chief Executive Officer
  source text: On October 20, 2022, SCYNEXIS announced that David Angulo, M.D., SCYNEXIS’s Chief Medical Officer, will become SCYNEXIS’s President and Chief Executive Officer and become a member of the Board of Directors effective January 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178253/000156459022034777/0001564590-22-034777-index.htm
- Executive change
  Marco Taglietti departed as President and Chief Executive Officer at SCYNEXIS INC.
  - Action: retire
  - Role: President and Chief Executive Officer
  source text: On October 14, 2022, Dr. Marco Taglietti announced to SCYNEXIS, Inc. that he plans to retire and will leave his position as President and Chief Executive Officer of SCYNEXIS, and will step down from the SCYNEXIS Board of Directors, on December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178253/000156459022034777/0001564590-22-034777-index.htm
- Executive change
  Ivor Macleod was appointed as Chief Financial Officer at SCYNEXIS INC.
  - Action: become
  - Role: Chief Financial Officer
  source text: On October 20, 2022, SCYNEXIS announced that Ivor Macleod, CPA, MBA, will become SCYNEXIS’s Chief Financial Officer, in which role he will become SCYNEXIS’s principal financial officer and principal accounting officer. Mr. Macleod’s anticipated first date of employment is October 24, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178253/000156459022034777/0001564590-22-034777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.